TABLE 2.
Descriptive Summary of Patterns of Care for Breast Cancer Survivors
| n (%) | ||||||
|---|---|---|---|---|---|---|
|
|
||||||
| Cohort 1 No RT† (n = 429) | Cohort 2 RT† (n = 307) | Cohort 3 Primary Therapy (n = 612) | ||||
|
|
|
|
||||
| Patient Characteristics | Ever in MH [210 (49.0)] |
Never in MH [219 (51)] |
Ever in MH [168 (54.7)] |
Never in MH [139 (45.3)] |
Ever in MH [334 (54.6)] |
Never in MH [278 (45.4)] |
| Mean no. months in MH (SD) | 10.9 (4.2) | 11.3 (4.4) | 11.4 (4.4) | |||
| Clinical characteristics | ||||||
| Comorbidity index | ||||||
| Score 0 | 60.0 (126) | 58.0 (127) | 58.3 (98) | 56.1 (78) | 58.7 (196) | 55.0 (153) |
| Score > 0 <1 | 31.4 (66) | 34.2 (75) | 36.3 (61) | 35.3 (49) | 33.5 (112) | 36.7 (102) |
| Score ≥ 1 <2 | 6.7 (14) | 5.9 (13) | 2.4 (4) | 6.5 (9)* | 5.1 (17) | 6.1 (17) |
| Score ≥ 2 | 1.9 (4) | 1.8 (4) | 3.0 (5) | 2.2 (3) | 2.7 (9) | 2.2 (6) |
| Tumor stage | ||||||
| Stage 0 | 28.6 (60) | 27.4 (60) | 22.6 (38) | 25.2 (35) | 25.7 (86) | 26.6 (74) |
| Stage 1 | 34.8 (73) | 34.7 (76) | 40.5 (68) | 46.8 (65) | 39.2 (131) | 40.3 (112) |
| Stage 2 | 23.3 (49) | 28.3 (62) | 28.0 (47) | 20.9 (29) | 25.1 (84) | 25.6 (71) |
| Stage unknown | 13.3 (28) | 9.6 (21) | 8.9 (15) | 7.2 (10) | 9.9 (33) | 7.5 (21) |
| Hormone receptor positive | 40.5 (85) | 37.0 (81) | 48.8 (82) | 46.0 (64) | 44.0 (147) | 43.2 (120) |
| Sociodemographic | ||||||
| Age mean (SD) | 48.1 (9.8) | 52.6 (9.1)*** | 48.9 (8.9) | 53.6 (9.0)*** | 48.4 (9.5) | 53.5 (8.8)*** |
| Race | ||||||
| White | 40.0 (84) | 47.5 (104) | 34.5 (58) | 48.2 (67)* | 37.7 (126) | 50.0 (139)*** |
| Black | 43.8 (92) | 41.1 (90) | 55.4 (93) | 36.0 (50)*** | 49.1 (164) | 38.1 (106)*** |
| Hispanic | 4.8 (10) | 1.8 (4)* | 3.6 (6) | 2.2 (3) | 4.8 (16) | 1.4 (4)** |
| Other | 4.3 (9) | 0.5 (1)*** | 2.4 (4) | 2.2 (3) | 2.4 (8) | 1.1 (3) |
| Multiple | 7.1 (15) | 9.1 (20) | 4.2 (7) | 11.5 (16)** | 6.0 (20) | 9.4 (26) |
| Urban residence | 61.9 (130) | 58.9 (129) | 63.7 (107) | 64.0 (89) | 62.9 (210) | 58.3 (162) |
| ABD classification | 58.1 (122) | 68.9 (151)** | 67.3 (113) | 75.5 (105) | 64.7 (216) | 76.3 (212)** |
| BCCCP participation | 3.3 (7) | 14.6 (32)*** | 7.1 (12) | 9.4 (13) | 5.1 (17) | 11.9 (33)*** |
| Fully dual eligible | 17.6 (37) | 36.5 (80)*** | 16.1 (27) | 47.5 (66)*** | 16.5 (55) | 47.5 (132)*** |
| Year of diagnosis | ||||||
| 2003 | 18.1 (38) | 20.5 (45) | 13.7 (23) | 23.0 (32)** | 18.3 (61) | 19.8 (55) |
| 2004 | 14.3 (30) | 15.5 (34) | 16.1 (27) | 25.2 (35)** | 15.6 (52) | 21.6 (60)* |
| 2005 | 21.9 (46) | 21.5 (47) | 23.2 (39) | 18.7 (26) | 22.8 (76) | 22.7 (63) |
| 2006 | 21.0 (44) | 19.6 (43) | 28.6 (48) | 18.0 (25)** | 23.4 (78) | 18.0 (50) |
| 2007 | 24.8 (52) | 22.8 (50) | 18.5 (31) | 15.1 (21) | 20.1 (67) | 18.0 (50) |
| Therapeutic characteristics | ||||||
| Surgery type | ||||||
| Both BCS and mastectomy | 35.2 (74) | 27.4 (60)* | 50.6 (85) | 52.5 (73) | 46.1 (154) | 45.7 (127) |
| No surgery | 19.0 (40) | 34.3 (75)*** | 15.5 (26) | 15.8 (22) | 10.5 (35) | 14.0 (39) |
| Breast conserving surgery only | 9.0 (19) | 10.5 (23) | 27.4 (46) | 25.9 (36) | 18.6 (62) | 20.5 (57) |
| Mastectomy only | 36.7 (77) | 27.9 (61)** | 6.6 (11) | 5.8 (8) | 24.9 (83) | 19.8 (55) |
| Chemotherapy | 41.0 (86) | 39.3 (86) | 61.3 (103) | 53.2 (74) | 51.8 (173) | 47.8 (133) |
| Receipt of recommended follow-up care | ||||||
| MM within 15 mo of diagnosis | 50.0 (105) | 40.2 (88)** | — | — | — | — |
| MM within 15 mo of RT | — | — | 85.1 (143) | 77.0 (107)* | — | — |
| Mean days to first MM | 281 (116) | 298 (81) | 157 (91) | 174 (94)* | — | — |
| Two physical exams within 15 mo of primary therapy | — | — | — | — | 96.7 (323) | 92.8 (258)** |
| Mean no. physical exams within 15 mo of primary therapy | — | — | — | — | 14.3 (8.3) | 15.6 (9.5)* |
Statistical significance of t tests and χ2 indicated by ***P < 0.01, **P < 0.05, *P < 0.1.
†
Receipt of radiation within 15 mo of diagnosis.
ABD indicates aged/blind/disabled; BCCCP, Breast and Cervical Cancer Control Program; BCS, breast conserving surgery; MH, medical home; MM, mammography; RT, radiation therapy.